Management of Indolent B-cell Lymphomas: A Review of Approved and Emerging Targeted Therapies

Indolent B-cell non-Hodgkin lymphomas (B-NHL) comprise a heterogenous group of lymphoproliferative disorders characterized by generally slow growth kinetics and a relapsing/remitting course. Survival outcomes have improved significantly over the last two decades, but indolent B-NHLs remain incurable with progressively shortening remissions following each line of therapy [1-4]. Until recently, the management of indolent B-NHL was not disease-specific. Combinations of non-targeted cytotoxic therapies and an anti-CD20 monoclonal (mAb) antibody have been used in front-line and relapsed settings across the whole spectrum of indolent B-NHL with similar activity seen regardless of subtype [5-8].

Source: Cancer Treatment Reviews - January 4, 2023 Category: Cancer & Oncology Authors: Elizabeth Smyth, Chan Y. Cheah, John F. Seymour Source Type: research